{"id":"commercial-acetaminophen","safety":{"commonSideEffects":[{"rate":null,"effect":"Hepatotoxicity (at high doses or chronic use)"},{"rate":null,"effect":"Rash"},{"rate":null,"effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Acetaminophen is believed to work primarily through inhibition of cyclooxygenase (COX) enzymes in the brain and spinal cord, reducing the production of prostaglandins that mediate pain and fever signaling. Unlike NSAIDs, it has minimal peripheral anti-inflammatory effects. The exact mechanism remains incompletely understood, but central nervous system effects on pain perception and thermoregulation are well-established.","oneSentence":"Acetaminophen reduces pain and fever by inhibiting prostaglandin synthesis in the central nervous system.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:06:51.120Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Mild to moderate pain"},{"name":"Fever reduction"}]},"trialDetails":[{"nctId":"NCT06356571","phase":"PHASE2","title":"A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Sanofi","startDate":"2025-03-17","conditions":"Plasma Cell Myeloma Refractory","enrollment":64},{"nctId":"NCT05704049","phase":"PHASE2","title":"A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2023-04-05","conditions":"Relapsed/Refractory Multiple Myeloma","enrollment":118},{"nctId":"NCT05405166","phase":"PHASE3","title":"SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2022-06-23","conditions":"Plasma Cell Myeloma Recurrent","enrollment":531},{"nctId":"NCT03365622","phase":"PHASE4","title":"Efficacy of IV Acetaminophen Versus Oral Acetaminophen","status":"COMPLETED","sponsor":"University of Rochester","startDate":"2018-08-08","conditions":"Nephrectomy","enrollment":214},{"nctId":"NCT01070212","phase":"NA","title":"Effects of Gum Chewing on Appetite and Digestion","status":"COMPLETED","sponsor":"Purdue University","startDate":"2010-02","conditions":"The Null Hypothesis is That Food Rheology Will Have no Effect on These Indices, The Alternate Hypothesis is That Increased Mechanical Stimulation Will Result in Stronger Satiation/Satiety and Reduced Energy Intake, It is Hypothesized That the Effects of Mastication Will be Less Evident in Obese Compared to Lean Individuals","enrollment":60},{"nctId":"NCT03879408","phase":"PHASE2","title":"Naproxen Sodium/Acetaminophen Proof of Concept Dosing Study","status":"COMPLETED","sponsor":"Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division","startDate":"2019-05-28","conditions":"Pain","enrollment":290},{"nctId":"NCT02735122","phase":"PHASE3","title":"Study of Acetaminophen (ACM) in Post-operative Dental Pain","status":"COMPLETED","sponsor":"Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division","startDate":"2016-04-30","conditions":"Post Operative Dental Pain","enrollment":420},{"nctId":"NCT03036904","phase":"PHASE1","title":"Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas","status":"COMPLETED","sponsor":"Weill Medical College of Cornell University","startDate":"2017-02-06","conditions":"Diffuse Large B-Cell Lymphoma, High Grade B-Cell Lymphoma","enrollment":31},{"nctId":"NCT02320708","phase":"PHASE2","title":"Study of Acetaminophen (ACE) in Post-operative Dental Pain","status":"COMPLETED","sponsor":"Johnson & Johnson Healthcare Products Division of McNEIL-PPC, Inc.","startDate":"2014-12-31","conditions":"Dental Pain","enrollment":240},{"nctId":"NCT03224403","phase":"PHASE3","title":"Randomized, Double-Blind, Single-Dose, Efficacy and Safety Study of Test Acetaminophen Tablet in Postoperative Dental Pain","status":"COMPLETED","sponsor":"Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division","startDate":"2017-07-19","conditions":"Post-operative Dental Pain","enrollment":664},{"nctId":"NCT03585374","phase":"PHASE3","title":"Trauma Acute Pain Treatment With Methoxyflurane Vaporized (PENTHROX®): Efficacy and Safety Study (MEDITA)","status":"COMPLETED","sponsor":"Mundipharma Pharmaceuticals srl","startDate":"2018-02-08","conditions":"Acute Traumatic Pain","enrollment":272},{"nctId":"NCT00719472","phase":"PHASE3","title":"A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE)","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2008-07","conditions":"Non-Hodgkin's Lymphoma","enrollment":451},{"nctId":"NCT01780428","phase":"PHASE3","title":"Phase III Study of the Safety and Efficacy of Cl-108 in the Treatment of Moderate to Severe Pain","status":"COMPLETED","sponsor":"Charleston Laboratories, Inc","startDate":"2013-01","conditions":"Pain, Nausea, Vomiting","enrollment":460},{"nctId":"NCT02462811","phase":"PHASE3","title":"A Double-Blind, Randomized, Active- and Placebo-Controlled, Multiple-Dose Multi-Center Phase 3 Study of the Safety and Efficacy of CL-108 in the Treatment of Moderate to Severe Acute Pain and Opioid-Induced Nausea and Vomiting (OINV)","status":"COMPLETED","sponsor":"Joseph Hazelton","startDate":"2014-09","conditions":"Pain, Nausea, Vomiting","enrollment":552},{"nctId":"NCT00406679","phase":"PHASE3","title":"Analgesic Efficacy, Safety and Tolerability of Two Paracetamol-containing Solutions in Post-Surgical Dental Pain","status":"COMPLETED","sponsor":"Baxter Healthcare Corporation","startDate":"2006-11","conditions":"Pain, Postoperative","enrollment":135}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":9,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Commercial ACM"],"phase":"phase_3","status":"active","brandName":"Commercial acetaminophen","genericName":"Commercial acetaminophen","companyName":"Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division","companyId":"johnson-johnson-consumer-inc-mcneil-consumer-healthcare-division","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Acetaminophen reduces pain and fever by inhibiting prostaglandin synthesis in the central nervous system. Used for Mild to moderate pain, Fever reduction.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}